<SEC-DOCUMENT>0001193125-24-224116.txt : 20240924
<SEC-HEADER>0001193125-24-224116.hdr.sgml : 20240924
<ACCEPTANCE-DATETIME>20240924073459
ACCESSION NUMBER:		0001193125-24-224116
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240924
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240924
DATE AS OF CHANGE:		20240924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		241317550

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d876211d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wve="http://www.wavelifesciences.com/20240924" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-271">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-24_to_2024-09-24">0001631574</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="wve-20240924.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-24_to_2024-09-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001631574</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-24</xbrli:startDate> <xbrli:endDate>2024-09-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-282">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt:datemonthdayyearen" id="ixv-283">September&#160;24, 2024</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-284">WAVE LIFE SCIENCES LTD.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:edgarprovcountryen" id="ixv-285">Singapore</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-286">001-37627</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-287">98-1356880</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-288">7 Straits View #12-00</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-289">Marina One</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-290">East Tower</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCountry" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:countrynameen" id="ixv-291">Singapore</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-292">018936</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-293">65</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-294">6236 3388</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration:underline">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:boolballotbox" id="ixv-295">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:boolballotbox" id="ixv-296">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:boolballotbox" id="ixv-297">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:boolballotbox" id="ixv-298">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:boolballotbox" id="ixv-299">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-300">$0 Par Value Ordinary Shares</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-301">WVE</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-24_to_2024-09-24" format="ixt-sec:exchnameen" id="ixv-302">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;24, 2024, Wave Life Sciences Ltd. (the &#8220;Company&#8221; or &#8220;Wave&#8221;) issued a press release announcing positive interim data from its Phase 2 <span style="white-space:nowrap">FORWARD-53</span> clinical trial of <span style="white-space:nowrap">WVE-N531,</span> the Company&#8217;s clinical candidate for exon 53 amenable Duchenne muscular dystrophy. A copy of the press release is attached hereto as Exhibit&#160;99.1 and incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The press release also indicated that Wave management will host an investor conference call at 8:30&#160;a.m. ET on September&#160;24, 2024, to discuss the interim results. For purposes of the call, and in connection with the announcement described above, the Company plans to share an investor slide presentation during the investor conference call, which will be available on the &#8220;Investors&#8221; section of the Company&#8217;s website at https://ir.wavelifesciences.com/. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information in this Item&#160;7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing</span>. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth in the press release referred to in Item&#160;7.01 above, other than the second, third, and sixth paragraphs thereof, is incorporated by reference into this Item&#160;8.01 of this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following exhibit relating to Item 7.01 is furnished and not filed: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d876211dex991.htm">Press Release issued by Wave Life Sciences Ltd. dated September&#160;24, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">WAVE LIFE SCIENCES LTD.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Paul B. Bolno, M.D.</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Paul B. Bolno, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September 24, 2024 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d876211dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876211g0924065450139.jpg" ALT="LOGO" STYLE="width:1.83889in;height:1.16667in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Wave Life Sciences Announces Positive Interim Data from <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> Clinical
Trial Evaluating <FONT STYLE="white-space:nowrap">WVE-N531</FONT> in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mean
muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy
patients who display milder disease </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of <FONT
STYLE="white-space:nowrap">WVE-N531</FONT> in myogenic stem cells and regeneration of myofibers </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Skeletal muscle concentrations of ~41,000 ng/g
combined with <FONT STYLE="white-space:nowrap">61-day</FONT> tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">WVE-N531</FONT> was safe and well tolerated: treatment-related adverse events were all mild, no serious adverse events, no
discontinuations and no oligonucleotide class-related events </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Wave expects feedback on a pathway to accelerated approval from regulators, as well
as the complete <FONT STYLE="white-space:nowrap">48-week</FONT> <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> data, in 1Q 2025 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Wave to host
investor conference call and webcast at 8:30 a.m. ET today </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAMBRIDGE, Mass.,</B><B></B><B>&nbsp;September 24, 2024</B>&nbsp;&#150;&nbsp;Wave Life
Sciences Ltd.&nbsp;(Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive interim data from the ongoing Phase 2 <FONT
STYLE="white-space:nowrap">FORWARD-53</FONT> study of <FONT STYLE="white-space:nowrap">WVE-N531,</FONT> which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
The interim analysis was conducted after 24 weeks of 10 mg/kg dosing every two weeks (Q2W), and <FONT STYLE="white-space:nowrap">WVE-N531</FONT> demonstrated substantial dystrophin expression and that it was safe and well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The high and consistent dystrophin levels at this interim timepoint are compelling and speak to the potential of
<FONT STYLE="white-space:nowrap">WVE-N531</FONT> for boys amenable to exon 53 skipping, where better therapeutic options are urgently needed,&#148; said Anne-Marie Li-Kwai-Cheung, MChem, MTOPRA, RAPS, Chief Development Officer at&nbsp;Wave Life
Sciences. &#147;It is also known that dystrophin is expressed as multiple functional isoforms and we are encouraged that the two isoforms observed on our Western Blot data are consistent with Becker muscular dystrophy patients who display milder
disease. This observation is further supported by our interim data showing myofiber regeneration and improvements in muscle health. We look forward to delivering data from the complete <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> study in the
first quarter of 2025, and would like to express our deepest gratitude to the boys, families and study staff who are participating in the study.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876211g0924065450139.jpg" ALT="LOGO" STYLE="width:1.83819in;height:1.16667in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Exon skipping is a promising approach to treat DMD and is compatible with all others that are approved
or in development. However, it has been challenging for the field to achieve dystrophin levels that can significantly improve clinical outcomes. Achieving mean muscle content-adjusted dystrophin of 9% is a meaningful step forward,&#148; said Laurent
Servais, MD, PhD, Professor of Paediatric Neuromuscular Disease at the University of Oxford and Principal Investigator in <FONT STYLE="white-space:nowrap">FORWARD-53.</FONT> &#147;The safe and tolerable profile and the option for monthly dosing is
also encouraging and has the potential to greatly contribute to quality of life of treated boys in comparison with current weekly dosing.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Detailed Interim Results from <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eleven boys amenable to exon 53 skipping (age <FONT STYLE="white-space:nowrap">5-11;</FONT> 10 ambulatory and 1
<FONT STYLE="white-space:nowrap">non-ambulatory)</FONT> are enrolled in the ongoing, open-label <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> trial. The study is designed to administer 10 mg/kg infusions of
<FONT STYLE="white-space:nowrap">WVE-N531</FONT> Q2W and muscle biopsies are taken after 24 and 48 weeks of dosing. Results from this interim analysis include: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety and Tolerability </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">WVE-N531</FONT> was safe and well tolerated. Treatment-related adverse events
(four events total in three participants) were mild in intensity. There were no serious adverse events and no study discontinuations due to any causes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no oligonucleotide class-related safety events. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Efficacy </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Dystrophin: </B>Dystrophin results from a <FONT STYLE="white-space:nowrap">pre-specified</FONT> analysis of
ambulatory boys showed: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mean absolute muscle content-adjusted dystrophin expression was 9.0% (range:
<FONT STYLE="white-space:nowrap">4.6-13.9%)</FONT> and mean absolute unadjusted dystrophin expression was 5.5% of normal (range: <FONT STYLE="white-space:nowrap">3.3-8.3%),</FONT> as measured by Western Blot. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The dystrophin expression was quantified from two isoforms consistent with those observed in Becker muscular
dystrophy patients who display milder disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">89% of ambulatory participants achieved muscle content-adjusted dystrophin levels of at least 5%.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exon skipping: </B>Mean exon skipping was 57% (range: <FONT STYLE="white-space:nowrap">31-75%)</FONT> as
measured by <FONT STYLE="white-space:nowrap">RT-PCR.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Localization: </B><FONT STYLE="white-space:nowrap">WVE-N531</FONT> was detected in myocyte nuclei in all
participants and in myogenic stem cells in the majority of participants. Myogenic stem cells are the progenitor cells for new myoblasts, which give rise to new myocytes and ultimately aid in skeletal muscle regeneration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Improvements in muscle health: </B>Participants showed multiple indicators of improvement in muscle health,
including an increase in the mean percentage of myocytes with internalized nuclei and an improvement in myofiber size and diameter between the previously completed Part A study and <FONT STYLE="white-space:nowrap">FORWARD-53.</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Serum biomarkers for muscle health:</B> Creatine kinase (CK) and aspartate aminotransferase (AST) are serum
biomarkers that are elevated in the presence of muscle damage. In the interim data, there were significant decreases in CK and AST levels from baseline. The reduction in CK was numerically larger than is typically seen with the introduction of
steroids in DMD. Changes in CK and AST were highly correlated (p&lt;0.0001). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Muscle concentration: </B>Mean muscle concentration was ~41,000 ng/g (~5,900 nM). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preclinical data for <FONT STYLE="white-space:nowrap">WVE-N531</FONT> demonstrate significantly higher drug
concentrations in the heart and diaphragm versus skeletal muscle, suggesting the <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> data from skeletal muscle biopsies may be underrepresenting activity in heart and diaphragm. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876211g0924065450139.jpg" ALT="LOGO" STYLE="width:1.83819in;height:1.16667in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Half-life: </B>The muscle tissue half-life of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is estimated to
be 61 days. Along with muscle concentration, this supports a monthly dosing regimen for <FONT STYLE="white-space:nowrap">WVE-N531</FONT> moving forward. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2025, Wave expects to complete the <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> trial and receive feedback from regulators on a
pathway to accelerated approval. Wave is also advancing a broader DMD pipeline of oligonucleotides for skipping other exons, with the goal of providing new and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment options for up to 40% of boys with DMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We
have long believed that our novel platform chemistry offered an opportunity to reimagine therapeutics for Duchenne, and we are looking forward to sharing further updates on <FONT STYLE="white-space:nowrap">WVE-N531,&#148;</FONT> said Paul Bolno, MD,
MBA, President and CEO of Wave Life Sciences. &#147;We are also hard at work advancing our lead RNA editing and RNAi programs, which offer differentiated, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
therapeutic approaches. In the fourth quarter of 2024, we expect <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> data for our <FONT STYLE="white-space:nowrap">WVE-006</FONT> program in <FONT
STYLE="white-space:nowrap">Alpha-1</FONT> antitrypsin deficiency. In the first quarter of 2025, we expect to initiate our clinical trial for <FONT STYLE="white-space:nowrap">WVE-007</FONT> &#150; a potentially breakthrough approach to obesity that
leverages GalNAc-siRNA to target INHBE and induce healthy weight loss with muscle maintenance. Finally, we are looking forward to our annual R&amp;D Day, which will take place this fall and where we will discuss the next wave of RNA innovations
being advanced by our organization.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Conference Call and Webcast </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave will host an investor conference call today at 8:30 a.m. ET to review the interim data from <FONT STYLE="white-space:nowrap">FORWARD-53.</FONT> A webcast
of the conference call can be accessed by visiting &#147;Investor Events&#148; on the investor relations section of the Wave Life Sciences website: <U>https://ir.wavelifesciences.com/events-publications/events</U>. Analysts planning to participate
during the Q&amp;A portion of the live call can join the conference call at the audio-conferencing link <U>available here</U>. Once registered, participants will receive the <FONT STYLE="white-space:nowrap">dial-in</FONT> information. Following the
live event, an archived version of the webcast will be available on the Wave Life Sciences website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">WVE-N531</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">WVE-N531</FONT> is an exon skipping oligonucleotide being developed
as a disease modifying treatment for boys with Duchenne muscular dystrophy amenable to exon 53 skipping. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> was designed using Wave&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> oligonucleotide chemistry modifications, including PN backbone chemistry. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is being investigated in the
ongoing Phase 2 <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> clinical trial, with additional data expected in the first quarter of 2025. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> has received Orphan Drug Designation and Rare Pediatric
Disease Designation from the U.S. Food&nbsp;&amp; Drug Administration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">FORWARD-53</FONT> is a potentially registrational, open-label, Phase 2 clinical trial evaluating <FONT
STYLE="white-space:nowrap">WVE-N531</FONT> as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. Eleven boys are currently enrolled. <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is being dosed at 10
mg/kg every two weeks, and endpoints include dystrophin expression after 24 and 48 weeks of treatment, as well as pharmacokinetic, safety and tolerability data, and functional assessments. <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> is fully
enrolled with final data from the study, including muscle biopsies after 48 weeks of treatment, expected in the first quarter of 2025. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876211g0924065450139.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Duchenne Muscular Dystrophy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duchenne muscular dystrophy (DMD) is a fatal <FONT STYLE="white-space:nowrap">X-linked</FONT> genetic neuromuscular disorder caused predominantly by <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-frame</FONT></FONT> deletions in the dystrophin gene, resulting in absent or defective dystrophin protein. Dystrophin protein is needed for normal muscle maintenance and operation.
Because of the genetic mutations in DMD, the body cannot produce functional dystrophin, which results in progressive and irreversible loss of muscle function, including the heart and lungs. Worldwide, DMD affects approximately one in 5,000 newborn
boys. Approximately <FONT STYLE="white-space:nowrap">8%-10%</FONT> of DMD patients have mutations amenable to treatment with an exon 53 skipping therapy. Exon skipping aims to address the underlying cause of DMD by promoting the production of
dystrophin protein to stabilize or slow disease progression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About</B><B></B><B>&nbsp;Wave Life Sciences </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave&#146;s
RNA medicines platform, PRISM<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent
disorders. Its toolkit of <FONT STYLE="white-space:nowrap">RNA-targeting</FONT> modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering
candidates that optimally address disease biology. Wave&#146;s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, <FONT STYLE="white-space:nowrap">Alpha-1</FONT> antitrypsin deficiency and Huntington&#146;s disease, as
well as a preclinical program in obesity. Driven by the calling to &#147;Reimagine Possible&#148;, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge,
MA. For more information on Wave&#146;s science, pipeline and people, please visit <U>www.wavelifesciences.com</U> and follow Wave on <U>X</U> (formerly Twitter) and <U>LinkedIn</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our understanding of the anticipated therapeutic benefit of
<FONT STYLE="white-space:nowrap">WVE-N531</FONT> as a therapy for DMD; our plan and estimated timing to engage regulators with the interim results and complete the trial and deliver the results of the complete trial; our understanding of the
dystrophin isoforms we are observing with <FONT STYLE="white-space:nowrap">WVE-N531;</FONT> our understanding of the safety profile of <FONT STYLE="white-space:nowrap">WVE-N531;</FONT> and the potential benefits of PRISM, including our novel PN
backbone chemistry modifications, and our stereopure oligonucleotides compared with stereorandom oligonucleotides. The words &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148;
&#147;plan,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target&#148; and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#146;s current expectations and beliefs and are subject
to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ
materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled &#147;Risk
Factors&#148; in Wave&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the&nbsp;Securities and Exchange Commission&nbsp;(SEC), as amended, and in other filings Wave makes with the&nbsp;SEC&nbsp;from
time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g876211g0924065450139.jpg" ALT="LOGO" STYLE="width:1.83819in;height:1.16667in;">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Rausch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-949-4827</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>krausch@wavelifesci.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alicia Suter </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-949-4817</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>asuter@wavelifesci.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DMD Community Contact:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelley Casey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-949-4830</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ccasey@wavelifesci.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>wve-20240924.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 11:38:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:wve="http://www.wavelifesciences.com/20240924"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.wavelifesciences.com/20240924"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20240924_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wve-20240924_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>wve-20240924_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 11:38:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>wve-20240924_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 11:38:53 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="wve-20240924.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g876211g0924065450139.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g876211g0924065450139.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N *X# 2(  A$! Q$!_\0
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M*\DU[X[:?I.M76GVNC37B6TAB:8SB,,RG!P-IXSWK-_X:'@_Z%J3_P #1_\
M$5:PM9J]A>UAW/;:*\2_X:'@_P"A:D_\#1_\177^"/B4_CA-3%IHWV>:RC1E
M22ZR)"V>,[?EZ=<&E+#58J\EH-5(MV3.^HK@;CXEFRLXI[K1)0\]@M[ D,X<
M-N+80G:-IVH[9Z84UWB,'C5QT8 UG*$H[E*2>PK*KJ58 JPP0>A%?'?C+0F\
M-^+M2TK!$<,Q,6>\9^9/T(K[%KPOX_Z!METWQ!$G# VDY [C+(?_ $(?@*Z<
M%4Y:G+W,:\;QOV.W^$&O_P!N> ;2.1]UQ8$VLF>N%^X?^^2!^!JW\4=?_P"$
M>\ ZA,C[;BY7[+#SSN?@D?1=Q_"O(O@7K_\ 9WBZ;297Q#J46%!/'F)DC]-P
M_*K7QZU_[7XAL]#B?,=C'YDH'_/1^@/T4#_OHU;H?[3;IN+VG[JYY%7HGP8U
M_P#L;QY#:R/BWU%#;-D\;^J'ZY&/^!5;^$_@B/Q18^(+BY12GV4VENS#A9FY
MW#W7 _[ZKSA3<:;J 8;H;JVER/5'4_S!%=TG&IS4S!7C:1]M5\F_$[7_ /A(
M?'NH7"/NM[=OLT'IM3C(]BVX_C7OFL^-XHOA2_B>!@LEQ:#R0#]V9_EQ_P !
M;/\ WR:^7]+T^?5]7M-/MQF>ZF6)/JQQFN/!4^5RG+IH;5Y7LD>__!C2HO#_
M (!N]?NQL-X6F9CU$,8('Z[S^(K@;W5I-1U*XO)3\\TA<\],G->E?$V_@\+^
M K+0;,[/."6Z#OY48&3_ .@C\37F_P /]-_MWQA8VS*&AC;SI@1D;%YP?8G
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M3K1TVW$J?:)\CG>_.#[@8'X5X5\8] _L7Q[<3QIMM]14728Z;CPX^NX$_P#
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45847101501120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001631574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 24,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">WAVE LIFE SCIENCES LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">U0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1356880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Straits View #12-00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Marina One<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">East Tower<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">SG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">018936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">6236 3388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">$0 Par Value Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WVE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" !</#A9/S7M%U@$   @$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V8;W/B-A#&OXK&U^FK2_P',"0%9@@A5^9R.1ISR4P[?2%L 9JS+5>2 _GV
M7=G$)CFSY@U8QOOXI]7Z69GA3LB?:LN8)OLD3M7(VFJ=7=NV"K<LH>I29"R%
M7]9")E3#4&YLE4E&HR(HB6W/<7P[H3RUQL/BW$*.AR+7,4_90A*5)PF5KS<L
M%KN1Y5IO)Q[Y9JO-"7L\S.B&!4S_R!821G:E$O&$I8J+E$BV'ED3]_K&ZYF
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !</#A999!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 7#PX69E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !</#A9/S7M%U@$   @$0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 7#PX69^@&_"Q @
MX@P   T              ( !G P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !</#A9EXJ[',     3 @  "P              @ %X#P  7W)E;',O+G)E
M;'-02P$"% ,4    " !</#A9'#AEZC\!   \ @  #P              @ %A
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 7#PX620>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 7#PX6660>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d876211d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d876211d8k.htm">d876211d8k.htm</File>
    <File>wve-20240924.xsd</File>
    <File>wve-20240924_lab.xml</File>
    <File>wve-20240924_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d876211d8k.htm": {
   "nsprefix": "wve",
   "nsuri": "http://www.wavelifesciences.com/20240924",
   "dts": {
    "inline": {
     "local": [
      "d876211d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "wve-20240924.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "wve-20240924_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wve-20240924_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-24_to_2024-09-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d876211d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-24_to_2024-09-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d876211d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.wavelifesciences.com//20240924/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-224116-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-224116-xbrl.zip
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M=7"TKN^O<@N"QBWL1V$77#ELC"C8"60&:J-,F$"H(FK '(R=7,)]PK4B8%E
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M>=.%7."XK'SJ?B=G)+X1NSKQ=4G*S46_9MIMNLB'_QR0^9>":O\/4$L#!!0
M   ( %P\.%F ;K'$<QH  +5V   1    9#@W-C(Q,61E>#DY,2YH=&WM75E3
M&TFV?E>$_D,&$W38<24AF<5L)JZ09)MHMA:XW7/?4E4I*9NJRNI:P.J'^>US
MSLG,6K1# W%[AHF)-DBU9)X\RW=6CK_>7IR?''_MM;LGU<KQ[=GM>>^D]UO]
MX*#1.M[2O\+G6^8"=GQZU?TG._W2N3J_ZG_:^/[U[+:WP6YN_WG>^[3AR4#4
MQT*.QLGAI8I\[FV<L&H%[N^((!'1R7'W[%=[\8-TD_'A?F-7!AN,>W(4P /$
M,-F@UUS;RWP>C6103U1XV R3(V9^'Z@D4;[^:*B"I![+/\5A*_]]R'WI30YO
MI2]B=BD>6%_Y'-[4/C_[<OEI(\)%;IP<GY[T?HSE0"8,=\R.MTY/CK>N3PH+
M*#S] SQ]:CTSR]DX^2D8Q.$1/@4VOF@?<^Y#0L$=9Q=?V$V_\VECM/]Q[T.K
M-6H>?-AI[NWN[#9;VP>-W\,1;N+VT\;YU9>KC3(U6XW][?W] QD<F5-H-5I[
M>WL?X0--UO+6"FNBO?U5XB(YO_-[P<[E4+ ;1XK @0O:0:!2^NE:Q3*1<,$9
MLH/T69<GG TCY;/CSU>7M]ENQC(1]3CDCC@,U$/$PXV3SU?][^U^M[Z[?;R%
MUYZP#O";=+A7K=Q&DGNL=\^]E"<R&*U^VO=?>_7+W>V6?98,V*F:Q.Q!)F/6
M39VQ" +!+M+823T>L>XD3B(5CB>L[8N #SS!$L5Z/U3 =K?9S9T,0WKM+/L\
M/XW/3BX$#ZH5'Q8'ZW#@8I"N.G=_3^-$N,PU:X4MB1]A).)8PC+5D!TTFIN,
M!RY+@WD7PQ6[C=W-FJ;!&/@'GQU+N"YP)HP[D8IC%O(HD8X,>9#$-20;9_B.
M4#AR*.&!/.#>!&XZ*C[Z@<?P+#^,9 R7P(N2!\5DK(:@).+\+8E^]:EP[D3$
M?$M\^Z!)M1+"\<)U<$YCQ5P9AQZ?,*"3"]?#KX+' @[A[#4.@5C7%3XL/HDX
MTM*'8P$N&*8>D[!7=2]\W!/L/Q91ZK.!A)LCV%H,#]?[@_,;"^XE8T-U3P$_
MRS]AE_K(-!]7*X_C9'^B1@)$@P%1?>8(SXOIW",!'XLH>SI<-Y0#7,\KT>SF
M3G@B 5'->=<!$ND5Q;BD?^VT:LUFDP6CK5&U CPS )OB:N*L%.J]5MWE$TN(
M1,9Q"O3EWK#NH4**TS!44<+@R)*Q-V$N:",0VI'"_\*)//#(/4)N=HQB82Z>
M<9R.1B).2IP/Q)C DT&3B7L1D+  !TYM!TX"#A=>B+1W)0_'$1_Y&:T76(=G
M(_:C=2!*:<R!4+C>!^ :T'&>(-X^9$DD>(+\7(^$1^S.W7M@'4T!E$@1P9UP
M$XICC04*N5ZJ-)ZZ$+^J5D!847')(#7$PG?"/0J @ I28 Z52!<XQ.-QG+W2
MO.J5N)5,&:A0X< [AT*X ^[<,44JCR?C!V !, +< 0'35&(\1+$'QB&3!N(&
M^BM1$>R9QT31:@5^2,:"M"&(@EC-U#O[]0<A[NPA/<%.(A>3JF[]PCXT/^R^
M*OV 0F,5)]6*#.Y!BA1)R1!X!42%.<@OFML&#@<9XPG;/]QN,M[P&ZQW"W>#
M0+_.>D]/.NV+T_Y9]TNOQBZ ZQHU,N=HT>D?C>MN1 A*%90F^[!30W+NX-?Z
MNY_^T=IM'NF?,QP$RML"H?/$;>AOWUWRV.5_'#*0P?? '<RJG'J<\)% 4Y$(
M9QPH3XTFQ"P\F, &G)0,:  F'$S%'2HNY*9!I+C+0H4V%)$0*-+^91L,D@L*
M*X WPRF 6@IB-+ALG,*.,[NC2<P-1L.G&(PF#49S,XR&KU*!UI?78[2U']:Q
M4+,<&2>I.\GMVQHZJI8IJ;%TQH =8,4@FT")V(*O:=4Q$/BI9CLY(OD$&1C,
MHKQ9H,'>=2^Z[PED<-1J!<PG#.:SKVT ^ASGQ++PQT">P$T=4@S#A#B&H2B3
MH6LUF3_:NAM9*P2J+9H0+M*7O/OEPW?D#!".1ROR$BJ)TP'PE.:+^= 0WY&,
M0?3 "UIB QKLQ:T6"-#.QR.D)\%/7$,!'!96[P&Y$-0DL' 99]1/X($AL&="
MQX9B SM ZN*3 */R.Y($>'Y15F!+CZ4PXC?BI&6L 9ANC$9Q(!(\?7@M/$ND
M "*8"HW5@Z_3"%!9 G@D !,CW!H28?\(3D&ZZ#J)^@6/).J2^L\/7-8[8Y'B
MLR_@!Q_^N;VZ[K=KK-^^OJFQSEB*(>LB=51(Z/-J.)0.O)TG"_52@VFZGR4D
M5UZLV!UL/-!,4: Z?&O8!ED:0%#J)1+,&!N"ZL - 3DS5*\9B'8(;U$I8!]A
M^ P/H.0!J %@A7NMV>!*]AU$5D3@DGDJT?I'G^>:?@);XB80]$ _H<%ND77T
MJS4DAE^':83G9+$B+&DPH265M&$\5@_(5A9 EY$U[KS@ ! 0+(']!FP0H+ZZ
MLZ@3N<<5'FC="!];UKCK0X5%BE;B4<*!#V4$-O:/%# IK!F4$*(!K6,>5.JY
MS)-WAI/IE&GCKA APM\1[@X>)ZP((?_7&(FR%/J\]>M W0R'F?+,8'.BU3'=
M2Q<V#*<;M;+5/?L5;*T)%54KC/Y_',+%$T^4M8WP9Y0-?A0"C]4'@%3OZ@,!
MM!6'W .8%F\ =-@*\25?^^SF[/^ ?ML;]KD4RCK\QP'];X-]/^O>?OVTT6HV
M-[-H4:=W>=OK/S&8M2R<]8)AH-:J,%"X[II848OO3X>X7BY69\Q!KV3E44.!
MCZ9\26:3$#<'1$ (!UP4!I9;2Z ..0#;H7HFA8%H4Z%XQUH/D6TGR"[<:D6A
MD .[9[JSP;ZJ![3+-;2,@'= DX.SYX!'Z8E@9+Q&XN>A%)ZKO0'0P*!A9VT5
MO=$!U!(#=TA0RIR4OE$4&0 $F4M@W:B5V_0LTC."!VR-> \&>38UB0K!"+@J
MM)JF9%W.>0HX'+#Y#:I "=)\T:T!LL/_1&H(&D"1FKCF "1Y$H'ANA0IT#X+
MBYF0B]'IWP+48  ?"=M=_8!WNG06UZ#64 5X["R#8YK<C]!I#:O4<I20(14-
M4O"@@9I#Z9E/$:^2I=4!E[+?+V/PQM#86?-D@<+8^&@Y1H"#'2%S>1,B?R0'
M:4)Z$'2I9[9+(08,;>&%:#<0'L .B0DC,'6!9D(GC2(R80#SLL5,J<*Y"&O_
MF=R<KD@X4,C-@K!]$8,ACY\<A[51SP4+WWN.=?<\"K2LQ%SL';I/*S>Q6V^U
MCNSZ 8IS?Z!=]0EQ0&L-2!BHH)[?]MX^3..=2'F>]C<*/E,-F%$$=8\/A/<4
M.B<8Y4;8(JQ=CT%=H3H16O>X/N@01$ZY=R&#81J;X-H3<"XX(400HWO +0UC
M,O:PRX3?P8EDG@U>MK.?.SB&L<O<54+KF:\$RL$#8''X"NQ_=G(#.B/1QWRK
MM88D$9X39,@?O??(S \"E]OVZ7G//NKTJM_M]>N -<X!J/<.[0]+USN]N0VF
M'_-IH[G!.KWS\^MVMWMV^27[_>:ZW;&_%W&,7D]?(Q[VB6T4@)($4 VTY_=*
MNN;"KKUY=S/?U&UWZLMMP$>_&H $1,G DL8]J- .YMW6FKIMS@N*#RI?BX=3
M^M:0EY4/ARWFE#4I_:S14Y#9%='3:N7=$,&V"7 F"H/DI#TB(4J1Y_<ZT(K.
M#%Z LA2@Q26] %_0MPN#KS;,JO7'3!#634FI8JS)X6F,( 2YF<X&_M/'_R!7
MOPG)FY#@6999;GGL/M9Z5_/A(KYZ:>7?PV@(=]ZT_1LCE[4]P.+,C3HD1)O_
MSJ(BA.&KH5L8X2<F(YX!0XMV$(@5\"9!6@PH89;M3=NN8M)6<QF7?OB/YE*L
M^V!\$"L/W<_'U7\@/*$"D'<1#T;B< UG8*>Q5V]M-PXV<^<FT%4.^2+FEY),
MO1?+2M E"*@FS*Y@M1QM-[;K^XWMS?=9]@>#SH+'::0#L\4X\3HFY4UZ_HNE
M!_WFQ3SZ1XHY,BIATI[JL@JE9*P 4F=9"RP>*^<BJI6UDA$LRT6\*?XWUEW,
MNOL'I#\+J*%4C&2"SNXZ)L%$H_%I"?R"11>[FPU,O[PQX!L\7@R/2UD8C9 )
MCI1K,,C:?]Q\A(EOU3_N%@!&7*T4#?S*^_NW]>M.OY&'HM^X^(V+%W/Q>:&^
M5C/QD^)\KDB$8PJ*_(ER)H"$*? AJ2(:Z_S*"CIP%]7EFA2!SW]7D<DD%6]M
ML(MYQ;P8?A]3L@N_HZHZ^@+37 %0 -XT\$"WQS53,#7"BBXLO\;XGKD"EZW7
MAG4</D^$-V&8%\2*Y:E*W6*!PQO2?I.S%7)VMJS\10O>=5% =/PC+RB2@2L=
M*IU%@9BJIB\7SF-E*::/=/86<TD1Y:2M8*&1"D6$A=F8&M1E[YKU"<M3-BI
MK0 +,$*,,H'/FGJOK?;!O=JB;E]@_FL@D@>L#=!"*>XQ].Y-LM(=E^%N6=O$
MW=<JZIM-?+^!M#>Q6RYV-RO[3 Y1]%@'TU$R$.Q.!B@K[SH_O]=,'Z/Q 4L
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M9S<7QS??YA3R?-S=/,) 14(#1LET'NHD+0!;,$9PTTF-F5G+A:E^X/GA="/
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M&++*8J0 !WG5_2=\2'^N]M]02P,$%     @ 7#PX64HQ--M# P  8@L  !
M  !W=F4M,C R-# Y,C0N>'-DO5;?;]LV$'XOT/_AIJ<-F$3+3HI9B%-D2P,$
M2+/"38>]%;1T=HA1I$92=OS?]TA)CNS$KIL,\XMIWGUWW_VDS]X_E!*6:*S0
M:A*ER2 "5+DNA%I,HMK&W.9"1._/W[XY^RF.X?+J^A9BN'>NLAECJ]4J*>9"
M62UK1Q9LDNN201QW^G_<?8&_&NL93%$BMP@EMPX-_%X+663#P7"4#M)A,NS#
M#')O#PKN,(,Q&YXP4CR!-,U&OV6G([CX"!^"&05WHL0^5E=K(Q;W#G[.?X&
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M.=_&9VJU^>*)&W6D_UQ*=HJF?S1$G?D?4$L#!!0    ( %P\.%E&[0#MO 0
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M-C(Q,61E>#DY,2YH=&U02P$"% ,4    " !</#A92C$TVT,#  !B"P  $
M            @ '6*P  =W9E+3(P,C0P.3(T+GAS9%!+ 0(4 Q0    ( %P\
M.%FU;6,L:08  '9&   4              "  4<O  !W=F4M,C R-# Y,C1?
M;&%B+GAM;%!+ 0(4 Q0    ( %P\.%E&[0#MO 0  #<L   4
M  "  >(U  !W=F4M,C R-# Y,C1?<')E+GAM;%!+!08     !0 % #T!  #0
%.@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d876211d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="wve-20240924.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-24_to_2024-09-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001631574</identifier>
        </entity>
        <period>
            <startDate>2024-09-24</startDate>
            <endDate>2024-09-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-271">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-24_to_2024-09-24"
      id="Hidden_dei_EntityCentralIndexKey">0001631574</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-282">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-283">2024-09-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-284">WAVE LIFE SCIENCES LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-285">U0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-286">001-37627</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-287">98-1356880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-288">7 Straits View #12-00</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-289">Marina One</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-290">East Tower</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-291">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-292">018936</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-293">65</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-294">6236 3388</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-295">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-296">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-297">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-298">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-299">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-300">$0 Par Value Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-301">WVE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-24_to_2024-09-24" id="ixv-302">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
